IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
13. September 2022 07:30 ET
|
IN8bio, Inc
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board
08. September 2022 07:30 ET
|
IN8bio, Inc
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio to Present at September Investor and Scientific Conferences
30. August 2022 16:15 ET
|
IN8bio, Inc
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
19. August 2022 09:20 ET
|
IN8bio, Inc
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock
16. August 2022 16:15 ET
|
IN8bio, Inc
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
12. August 2022 16:15 ET
|
IN8bio, Inc
Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the ASGCT Annual Meeting.Presented data from Phase 1 clinical trial of INB-200...
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock
11. August 2022 22:05 ET
|
IN8bio, Inc
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients
27. Juli 2022 07:00 ET
|
IN8bio, Inc
All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year.Patients...
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
21. Juli 2022 07:00 ET
|
IN8bio, Inc
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cellsPatent portfolio broadly covers...
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
12. Juli 2022 08:00 ET
|
IN8bio, Inc
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...